As per a BSE filing by Alembic, USFDA conducted the inspection at active pharmaceutical ingredient (API) facility at Karkhadi from May 14-18, 2018.
"This was a scheduled inspection and at the end of the inspection, USFDA issued a Form 483 with one observation," the company said.
As per USFDA, Form 483 is issued at the conclusion of an inspection, notifying a company's management of objectionable conditions at the facility.
Shares of Alembic Pharmaceuticals today settled at Rs 465 per scrip on BSE, down 2.23 per cent from the previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)